Merck Pipeline & Clinical Trials

Downside risk: What's the chance we get 0 approvals? (important for portfolio planning)
Upside potential: Could we hit 5+ approvals if things go well?
Confidence width: A narrow range (2-4) means more predictable; wide range (0-6) means higher uncertainty

Welireg (belzutifan) + Keytruda (pembrolizumab) Adjuvant clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence sNDA + sBLA

Jun 19, 2026 24 days Calendar →

Winrevair (sotatercept) Recently diagnosed pulmonary arterial hypertension (PAH, HYPERION label update) sBLA

Sep 21, 2026 118 days Calendar →

Welireg (belzutifan) + Lenvima (lenvatinib) Previously treated advanced ccRCC post-PD-1/PD-L1 therapy sNDA

Oct 4, 2026 131 days Calendar →

Ifinatamab deruxtecan (I-DXd) Extensive-stage small cell lung cancer (ES-SCLC) after platinum chemo BLA

Oct 10, 2026 137 days Calendar →

Merck Pipeline